Gene · 54890
Papers4,144
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
901 to 920 of 4,144
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Post-transcriptional regulation of erythropoiesis. | Blood Sci | 2023 | 37546708 | PubTator, text mining | PubMed |
| Biological function and research progress of N6-methyladenosine binding protein heterogeneous nuclear ribonucleoprotein A2B1 in human cancers. | Front Oncol | 2023 | 37546413 | PubTator, text mining | PubMed |
| Using integrated analysis from multicentre studies to identify RNA methylation-related lncRNA risk stratification systems for glioma. | Cancer Cell Int | 2023 | 37542290 | PubTator, text mining | PubMed |
| METTL14‑mediated RNA methylation in digestive system tumors. | Int J Mol Med | 2023 | 37539726 | PubTator, text mining | PubMed |
| Comprehensive analysis of m6A methylomes in idiopathic pulmonary arterial hypertension. | Epigenetics | 2023 | 37537976 | PubTator, text mining | PubMed |
| Genetic and pharmacological inhibition of METTL3 alleviates renal fibrosis by reducing EVL m6A modification through an IGF2BP2-dependent mechanism. | Clin Transl Med | 2023 | 37537731 | PubTator, text mining | PubMed |
| Enhancer RNAs: mechanisms in transcriptional regulation and functions in diseases. | Cell Commun Signal | 2023 | 37537618 | PubTator, text mining | PubMed |
| Promoting axon regeneration by inhibiting RNA N6-methyladenosine demethylase ALKBH5. | Elife | 2023 | 37535403 | PubTator, text mining | PubMed |
| METTL14 reverses liver fibrosis by inhibiting NOVA2 through an m6A-YTHDF2-dependent mechanism. | Hepatol Commun | 2023 | 37534933 | PubTator, text mining | PubMed |
| The m6A Reader YTHDF1 Accelerates the Osteogenesis of Bone Marrow Mesenchymal Stem Cells Partly via Activation of the Autophagy Signaling Pathway. | Stem Cells Int | 2023 | 37533592 | PubTator, text mining | PubMed |
| TRMT61B rs4563180 G>C variant reduces hepatoblastoma risk: a case-control study of seven medical centers. | Aging (Albany NY) | 2023 | 37531210 | PubTator, text mining | PubMed |
| Identification of the relationship between single-cell N6-methyladenosine regulators and the infiltrating immune cells in esophageal carcinoma. | Heliyon | 2023 | 37529341 | PubTator, text mining | PubMed |
| Corrigendum to: USP36 promotes tumorigenesis and drug sensitivity of glioblastoma by deubiquitinating and stabilizing ALKBH5. | Neuro Oncol | 2023 | 37527558 | PubTator, text mining | PubMed |
| Corrigendum to "m6A hypomethylation of DNMT3B regulated by ALKBH5 promotes intervertebral disc degeneration via E4F1 deficiency". | Clin Transl Med | 2023 | 37525589 | PubTator, text mining | PubMed |
| Development and validation of a novel prognostic signature based on m6A/m5C/m1A-related genes in hepatocellular carcinoma. | BMC Med Genomics | 2023 | 37525171 | PubTator, text mining | PubMed |
| ALKBH5 facilitates CYP1B1 mRNA degradation via m6A demethylation to alleviate MSC senescence and osteoarthritis progression. | Exp Mol Med | 2023 | 37524872 | PubTator, text mining | PubMed |
| The therapeutic targets of N6-methyladenosine (m6A) modifications on tumor radioresistance. | Discov Oncol | 2023 | 37522921 | PubTator, text mining | PubMed |
| Abnormal Decrease of Macrophage ALKBH5 Expression Causes Abnormal Polarization and Inhibits Osteoblast Differentiation. | Stem Cells Int | 2023 | 37519314 | PubTator, text mining | PubMed |
| CRISPR-based m6A modification and its potential applications in telomerase regulation. | Front Cell Dev Biol | 2023 | 37519297 | PubTator, text mining | PubMed |
| m6A methyltransferase KIAA1429 accelerates oral squamous cell carcinoma via regulating glycolysis and ferroptosis. | Transl Oncol | 2023 | 37517144 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/54890/papers?page=46